JP2013516978A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516978A5 JP2013516978A5 JP2012548518A JP2012548518A JP2013516978A5 JP 2013516978 A5 JP2013516978 A5 JP 2013516978A5 JP 2012548518 A JP2012548518 A JP 2012548518A JP 2012548518 A JP2012548518 A JP 2012548518A JP 2013516978 A5 JP2013516978 A5 JP 2013516978A5
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- seq
- preproendothelin promoter
- mouse preproendothelin
- transgene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 96
- 241000701161 unidentified adenovirus Species 0.000 claims description 47
- 101800004490 Endothelin-1 Proteins 0.000 claims description 42
- 108091033319 polynucleotide Proteins 0.000 claims description 31
- 102000040430 polynucleotide Human genes 0.000 claims description 31
- 239000002157 polynucleotide Substances 0.000 claims description 31
- 230000003362 replicative effect Effects 0.000 claims description 25
- 239000002773 nucleotide Substances 0.000 claims description 23
- 125000003729 nucleotide group Chemical group 0.000 claims description 23
- 108700019146 Transgenes Proteins 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 16
- 238000012258 culturing Methods 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 150000007523 nucleic acids Chemical group 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 230000001023 pro-angiogenic effect Effects 0.000 claims description 6
- 108700025910 Suicide Transgenic Genes Proteins 0.000 claims description 5
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000004115 adherent culture Methods 0.000 claims description 3
- 230000033115 angiogenesis Effects 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 230000001640 apoptogenic effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000011031 large-scale manufacturing process Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 3
- 238000004114 suspension culture Methods 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000004255 ion exchange chromatography Methods 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 241001135569 Human adenovirus 5 Species 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29415810P | 2010-01-12 | 2010-01-12 | |
| US61/294,158 | 2010-01-12 | ||
| PCT/IB2011/050137 WO2011086509A1 (en) | 2010-01-12 | 2011-01-12 | Methods of producing adenovirus vectors and viral preparations generated thereby |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013516978A JP2013516978A (ja) | 2013-05-16 |
| JP2013516978A5 true JP2013516978A5 (cg-RX-API-DMAC7.html) | 2014-02-27 |
| JP6009357B2 JP6009357B2 (ja) | 2016-10-19 |
Family
ID=43982270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548518A Expired - Fee Related JP6009357B2 (ja) | 2010-01-12 | 2011-01-12 | アデノウイルスベクターの生産方法およびそれによって生成されるウイルス調製物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20130052165A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2523681A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6009357B2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL220922B (cg-RX-API-DMAC7.html) |
| SG (2) | SG182490A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011086509A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| EP1436313B1 (en) | 2001-10-19 | 2010-09-22 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| WO2008015675A2 (en) | 2006-07-31 | 2008-02-07 | Vascular Biogenics Ltd. | Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia |
| SG182367A1 (en) | 2010-01-05 | 2012-08-30 | Vascular Biogenics Ltd | Methods for use of a specific anti-angiogenic adenoviral agent |
| SG182366A1 (en) | 2010-01-05 | 2012-08-30 | Vascular Biogenics Ltd | Compositions and methods for treating glioblastoma gbm |
| LT2908865T (lt) * | 2012-10-17 | 2019-01-10 | Vascular Biogenics Ltd. | Fas-chimerą ekspresuojantis adenovirusas ir jo panaudojimas vėžio gydymo būduose |
| CN103012591B (zh) * | 2012-12-12 | 2014-05-14 | 武汉吉爱生物技术有限公司 | 抗Benzonase单克隆抗体、其制备方法和应用 |
| ES2774964T3 (es) | 2013-02-04 | 2020-07-23 | Vascular Biogenics Ltd | Métodos para inducir la capacidad de respuesta a un agente antiangiogénico |
| KR102200278B1 (ko) | 2013-03-15 | 2021-01-07 | 더 칠드런스 호스피탈 오브 필라델피아 | 무혈청 현탁 세포 배양 시스템에서 재조합 렌티바이러스 벡터를 생성하기 위한 확대가능한 제작 방법 |
| CN107603956A (zh) * | 2017-08-24 | 2018-01-19 | 乾元浩生物股份有限公司 | 一种禽腺病毒纸片载体潮汐式悬浮培养方法 |
| CN107630004B (zh) * | 2017-09-01 | 2021-01-15 | 康希诺生物股份公司 | 降低可复制性腺病毒产生的细胞株及构建方法和应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5747340A (en) | 1994-06-03 | 1998-05-05 | Syntex (U.S.A.) Inc. | Targeted gene expression using preproendothelin-1 promoters |
| CA2230655C (en) * | 1995-08-30 | 2008-06-17 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
| KR100503701B1 (ko) * | 1996-11-20 | 2005-07-26 | 인트로겐 테라페티스, 인코퍼레이티드 | 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법 |
| KR100762033B1 (ko) * | 1998-12-31 | 2007-10-04 | 아방티 파르마 소시에테 아노님 | 바이러스 입자의 분리방법 |
| US6168941B1 (en) * | 2000-04-07 | 2001-01-02 | Genvec, Inc. | Method of producing adenoviral vector stocks |
| US20070286845A1 (en) * | 2000-11-17 | 2007-12-13 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| AU2002348151A1 (en) * | 2001-11-05 | 2003-05-19 | Genvec, Inc. | Viral vector production methods and compositions |
| US7459154B2 (en) * | 2002-12-26 | 2008-12-02 | Cell Genesys, Inc. | Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| JP2008528006A (ja) * | 2005-01-28 | 2008-07-31 | アポロ ライフ サイエンシズ リミテッド | 分子およびそのキメラ分子 |
| WO2008015675A2 (en) | 2006-07-31 | 2008-02-07 | Vascular Biogenics Ltd. | Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia |
-
2011
- 2011-01-12 EP EP11706326A patent/EP2523681A1/en not_active Withdrawn
- 2011-01-12 SG SG2012051496A patent/SG182490A1/en unknown
- 2011-01-12 JP JP2012548518A patent/JP6009357B2/ja not_active Expired - Fee Related
- 2011-01-12 SG SG10201500015TA patent/SG10201500015TA/en unknown
- 2011-01-12 US US13/521,691 patent/US20130052165A1/en not_active Abandoned
- 2011-01-12 WO PCT/IB2011/050137 patent/WO2011086509A1/en not_active Ceased
-
2012
- 2012-07-12 IL IL220922A patent/IL220922B/en active IP Right Grant
-
2013
- 2013-03-14 US US13/826,396 patent/US20130295053A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013516978A5 (cg-RX-API-DMAC7.html) | ||
| JP5465331B2 (ja) | 高細胞密度の培養物からのアデノウイルスの精製方法 | |
| JP5393896B2 (ja) | アデノウイルス粒子の精製方法 | |
| ES2329607T3 (es) | Metodos de purificacion de virus. | |
| ES2317517T3 (es) | Purificacion de virus usando ultrafiltracion. | |
| JP5855564B2 (ja) | オルソポックスウイルスの製造および精製方法 | |
| CN104694573B (zh) | 利用CRISPR/Cas9抑制HIV‑1感染原代淋巴细胞的方法 | |
| JP6009357B2 (ja) | アデノウイルスベクターの生産方法およびそれによって生成されるウイルス調製物 | |
| KR20150122674A (ko) | 아데노바이러스의 생산 방법 | |
| JP2000514290A (ja) | 組換えアデノウイルスの製造方法 | |
| KR20140139509A (ko) | 터미널 말단이 변경된 재조합 아데노바이러스의 배치 | |
| CN110741081B (zh) | 肿瘤选择性tata盒和caat盒突变体 | |
| CN104846013A (zh) | 一种复制缺陷型人55型腺病毒载体及其制备方法和应用 | |
| WO2015128500A1 (en) | A process for the preparation of group b adenoviruses | |
| CN102284058A (zh) | 复制缺陷型抗ev71和ca16病毒双价疫苗的制备方法 | |
| CN116286685A (zh) | 一种基于CRISPR-Cas9技术的表达H9N2禽流感病毒XZ491毒株HA蛋白的重组血清4型禽腺病毒及其制备方法 | |
| US20080267992A1 (en) | Sars Virus Vaccine with Adenovirus Carrier and Preparation Method Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine | |
| CN101768576B (zh) | Hsv1-tk基因重组溶瘤腺病毒及其制备方法和应用 | |
| CN107164337B (zh) | 含ccl5和sstr2基因的重组痘病毒及其制备方法 | |
| US20050079158A1 (en) | Construct of anti-cancer recombinant adenovirus, method for preparing the same and use thereof | |
| CN103881985B (zh) | 狂犬病病毒era减毒疫苗突变株及其制备方法和狂犬病活疫苗 | |
| CN103305534A (zh) | 一种水貂肠炎病毒反向遗传学操作系统及其应用 | |
| WO2012108195A1 (ja) | 遺伝子導入用ウイルスベクターの製造方法 | |
| CN101948516B (zh) | 一种以痘苗病毒载体为基础的反向遗传学系统建立及应用 | |
| CN1272440C (zh) | 以肿瘤细胞plk1为药靶的抗癌重组腺病毒的构建及用途 |